Seeing Is Believing
Currently out of the existing stock ratings of Kevin Degeeter, 114 are a BUY (93.44%), 7 are a HOLD (5.74%), 1 are a SELL (0.82%).
Analyst Kevin Degeeter, currently employed carries an average stock price target met ratio of 43.55% that have a potential upside of 44.91% achieved within 134 days. Previously, Kevin Degeeter worked at OPPENHEIMER.
Kevin Degeeter’s has documented 221 price targets and ratings displayed on 30 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ANTX, AN2 Therapeutics at 13-Sep-2023.
Analyst best performing recommendations are on DMTK (DERMTECH).
The best stock recommendation documented was for NVTA (INVITAE CORP) at 1/12/2021. The price target of $51 was fulfilled within 1 day with a profit of $3.41 (7.17%) receiving and performance score of 71.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$2
$0.97 (94.17%)
$6
7 months 5 days ago
(16-May-2024)
1/5 (20%)
$0.89 (80.18%)
153
Buy
$6
$4.97 (482.52%)
9 months 14 days ago
(07-Mar-2024)
1/6 (16.67%)
$4.79 (395.87%)
157
Hold
$6
1 years 1 months 8 days ago
(13-Nov-2023)
2/4 (50%)
$4.15 (224.32%)
123
Buy
$80
1 years 11 months 16 days ago
(05-Jan-2023)
2/3 (66.67%)
$58.3 (268.66%)
204
Buy
2 years 5 months 3 days ago
(18-Jul-2022)
2/3 (66.67%)
$64.6 (85.68%)
137
What Year was the first public recommendation made by Kevin Degeeter?